News Releases

Wednesday, May 24, 2017

Harrington Discovery Institute at University Hospitals opens call for Harrington Rare Disease Scholar Award

CLEVELAND – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – is pleased to announce its request for proposals for the Harrington Rare Disease Scholar Award. The Harrington Rare Disease Scholar Award supports breakthrough research for therapeutic discoveries in rare diseases. The program is sponsored by Takeda Pharmaceutical Company Limited (TSE: 4502) and overseen by Harrington Discovery Institute, a nonprofit initiative that helps academic researchers translate their most promising inventions into new medicines.

“We are excited to launch this new program with Takeda,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. “The Harrington Rare Disease Scholar Award provides a unique opportunity to advance cutting-edge research in rare diseases into life-saving treatments.”

Thursday, May 18, 2017

University Hospitals celebrated opening of American Cancer Society Wig Salon

CLEVELAND –  University Hospitals Seidman Cancer Center celebrated the grand opening of their newest patient service, a free nail and wig salon called Le Salon on Thursday, May 18.  Wigs will be provided at the salon through the American Cancer Society Free Wig Salon program. The American Cancer Society provides this free community resource to help cancer patients manage the impact of cancer on their lives. The goal of the program is to provide a quality new wig free of charge in a safe comfortable environment.
“UH Seidman Cancer Center is a wonderful partner and we are pleased to be able to work together to help patients with some of the appearance related side effects of cancer treatment. Losing your hair due to treatment can be so devastating and we are happy to be able to ease this burden,” said Sarah Wells, executive director of the American Cancer Society.
The American Cancer Society can provide a human hair or synthetic hair wig, based on the woman’s preferences. In partnership with Pantene, the Society has provided more than 42,000 real-hair wigs to women coping with hair loss due to cancer.

Wednesday, May 17, 2017

DAWN trial results demonstrate dramatic reduction in disability from stroke up to 24 hours of onset

CLEVELAND – Results from the DAWN stroke trial presented at the European Stroke Organization Conference (ESOC) provide compelling evidence that selected patients suffering a major ischemic stroke recovered significantly better with mechanical retrieval of the blood clot with medical therapy compared with medical therapy alone when initiated past the current guidelines of within 6 hours and up to 24 hours of the stroke.
University Hospitals Cleveland Medical Center was one of the top seven recruiting sites in the multi-site study that enrolled a total of 206 patients in the nation. The results showed that patients treated with the retrieval system, known as mechanical thrombectomy, had significantly decreased post-stroke disability and improved functional independence at 90 days compared to medical management alone.

University Hospitals exceeds campaign goal of $1.5 billion
Saturday, May 13, 2017

University Hospitals exceeds campaign goal of $1.5 billion

CLEVELAND – University Hospitals (UH) has exceeded its Discover the Difference: The Campaign for University Hospitals goal of $1.5 billion. This milestone represents the culmination of a multi-year effort made possible through the generosity of more than 83,500 donors contributing nearly 185,000 gifts totaling $1,511,586,803. Donor support ranged from $1 to $72.6 million.

“University Hospitals’ unwavering commitment to our community has endured for 150 years. And the community’s confidence in UH is equally remarkable,” says Thomas F. Zenty III, CEO, University Hospitals. “The extraordinary success of the Discover the Difference campaign is a tribute to the great generosity of our community, and their gifts have transformed the lives of our families, friends and neighbors. We thank them for their strong belief in our mission throughout the campaign.”

Friday, April 28, 2017

Dr. Andrew Sloan presents encouraging results of Laser Interstitial Thermal Therapy (LITT) clinical studies for difficult-to-access brain lesions

CLEVELAND – Andrew Sloan, MD, Director of the Brain Tumor and NeuroOncology Center at University Hospitals Cleveland Medical Center, presented new data supporting use of the NeuroBlate system for brain lesions at the 2017 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Los Angeles on April 26. 
Dr. Sloan, who is also Professor and Vice Chair of the Department of Neurosurgery at Case Western Reserve University School of Medicine, presented on Monteris Medical’s LAISE study results. He delivered an oral presentation titled “Laser Ablation in Stereotactic Neurosurgery (LAISE): A Multi-Institutional Retrospective Analysis of LITT for Glioma” which described the results of 97 patients whose lesions were ablated with the NeuroBlate system.
Of the lesions analyzed, 48 percent were deep-seated, 57.8 percent were considered inoperable, and 1 percent were not suitable for chemotherapy. 

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.